# Evaluation of a New Agent for Treatment of Advanced Stage Breast Cancer

> **NCT00313248** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 65 (actual)

## Conditions studied

- Breast Neoplasm

## Interventions

- **DRUG:** Sagopilone (ZK 219477)
- **DRUG:** Sagopilone (ZK 219477)

## Key facts

- **NCT ID:** NCT00313248
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2008-10
- **Final completion:** 2008-11
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2015-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00313248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00313248, "Evaluation of a New Agent for Treatment of Advanced Stage Breast Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00313248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*